Chronobiological approach to the treatment of patients with benign prostate hyperplasia and chronic prostatitis: results of a morphological examination

2021 ◽  
Vol 11 (2) ◽  
pp. 113-122
Author(s):  
Andrey V. Kuzmenko ◽  
Timur A. Gyaurgiev ◽  
Ivan I. Barannikov ◽  
Boris E. Leybovich
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Standard Therapy ◽  
Chronic Prostatitis ◽  
Inflammatory Process ◽  
Comparison Group ◽  
Prostatic Hyperplasia ◽  
Morphological Examination ◽  
Prostate Hyperplasia ◽  
The Individual ◽  
Benign Prostate

MATERIALS AND METHODS: 60 patients with benign prostatic hyperplasia (BPH) and category II chronic prostatitis (NIH, 1995) were examined. The average age of the patients was 60.55.5 years. The patients were divided into two groups of 30 people each. The comparison group (GC) included patients who received standard therapy with drugs from the group of alpha-blockers and fluoroquinolones. The main group (MG) consisted of patients who received standard therapy in combination with physiotherapy sessions with the device SMART-PROST, which were carried out in the acrophase of the chronorhythm. After the end of the course of therapy all patients underwent transurethral resection of the prostate, after which a morphological and morphometric (immunohistochemical) study of the obtained material was carried out. RESULTS: According to the results of the morphological and morphometric examination of the histological material in patients of the CG and MG, statistically significant differences were revealed in all the studied parameters, which testify to the persistence of signs of the inflammatory process in the CG, while in the MG, the severity of inflammation was significantly lower. CONCLUSION: According to the results of the study, personalized complex therapy of patients with benign prostatic hyperplasia in combination with chronic prostatitis using a combined physiotherapeutic effect of the SMART-PROST device, taking into account the individual chronobiological characteristics of patients, allows to more effectively arrest the inflammatory process in the prostate tissue, which can lead to a decrease in the number of postoperative complications. However, the last statement requires further more detailed study.

scholarly journals Periodontal disease and risk of benign prostate hyperplasia: a cross-sectional study

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Lan Wu ◽  
Bing-Hui Li ◽  
Yun-Yun Wang ◽  
Chao-Yang Wang ◽  
Hao Zi ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Periodontal Disease ◽  
Subgroup Analysis ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Health Examination ◽  
Control Analysis ◽  
Prostate Hyperplasia ◽  
Benign Prostate

Abstract Background Both periodontal disease and benign prostatic hyperplasia are age-related diseases that affect millions of people worldwide. Hence, this study aimed to investigate the association between periodontal disease and the risk of benign prostatic hyperplasia. Methods A total of 4930 participants were selected from an available health examination that was carried out in 2017, only males were considered for further analysis. All eligible males were divided into benign prostatic hyperplasia and normal groups, the benign prostatic hyperplasia group was then divided into prostate volume ≤ 60 g and > 60 g subgroups; all their periodontal status was extracted and then into normal (CPI score of 0), periodontal disease (CPI score between 1 and 4), and periodontitis (CPI score between 3 and 4) groups. The correlation between periodontal disease and benign prostatic hyperplasia was investigated using logistic regression analyses and greedy matching case-control analysis. Subgroup analysis based on prostate volume was also performed. All analyses were conducted with SAS 9.4 software. Results A total of 2171 males were selected for this analysis. The presence of periodontal disease significantly increased the risk of benign prostatic hyperplasia by 1.68 times (OR = 1.68, 95% CI: 1.26–2.24), and individuals with periodontitis showed a higher risk (OR = 4.18, 95% CI: 2.75–6.35). In addition, among matched cases and controls, this association remained robust (periodontal disease: OR = 1.85, 95% CI: 1.30–2.64; periodontitis: OR = 4.83, 95% CI: 2.57–9.07). Subgroup analysis revealed that periodontal disease significantly increased benign prostate hyperplasia risk as well (for prostate volume ≤ 60 g: OR = 1.64, 95% CI: 1.22–2.20; for volume > 60 g: OR = 2.17, 95% CI: 1.04–4.53), and there was a higher risk in the group with a prostate volume greater than 60 g. Conclusion Periodontal disease is significantly and positively associated with an increased risk of benign prostatic hyperplasia. Further validation studies should be performed to explore the relationship between periodontal treatment and benign prostate hyperplasia.

scholarly journals Modern Approaches to Treatment of Abacterial Prostatitis and Benign Prostate Hyperplasia Using a Prostate Extract of Bulls

Health of Man ◽  
2021 ◽  
pp. 32-37
Author(s):  
Ihor Gorpynchenko ◽  
Volodymyr Spyrydonenko
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Chronic Prostatitis ◽  
Prostate Gland ◽  
Prostatic Hyperplasia ◽  
Actual State ◽  
Clinical Effects ◽  
Prostate Hyperplasia ◽  
Metabolism Regulation ◽  
Anti Inflammatory ◽  
Positive Effect

The formation of the inflammatory process in the prostatic tissue in most cases occurs with minimal clinical manifestations, and their clinical and diagnostic verification often does not reflect the actual state of the problem. This requires a search for clinical solutions in order to minimize the formation of inflammatory processes and the regulation of trophic functions in the compromised tissues of the prostate gland. The use of conservative therapy in people with chronic prostatitis and benign prostatic hyperplasia is considered the leading preventive and therapeutic method, therefore, the search for new and improvement of existing pharmacological drugs is an urgent issue. The action of specific amino acid molecules of the mediator link of the bioregulation system – cytomedines, is due to the regulatory capabilities of low molecular weight peptides, which are multifunctional, capable of inducing the release of other regulatory substances and the formation of the so-called. «Peptide cascade» in a certain place in a short time. Their final effect is not enhanced by excessive intake, is not dose-dependent and is expressed by a complete systemic effect on general physiological processes (apoptosis, proliferation, various types of metabolism, regulation of genetic information). Vitaprost is an extract of the prostate gland of bulls, lyophilized from an aqueous solution, among the organ peptides it stands out with high clinical efficacy and the absence of side reactions. Its main clinical effects are considered: anti-inflammatory (the ability to reduce edema and leukocyte infiltration in the tissues of the prostate gland), vascular (able to improve the processes of microcirculation and platelet-vascular homeostasis), trophic (a positive effect on spermatogenesis in the form of an increase in the functional activity of spermatozoa and the qualitative characteristics of sperm) , immunoregulatory (stimulates the activity of the humoral link of immunity and some factors of the body’s resistance), antimicrobial (stimulates the antimicrobial activity of neutrophils), neurotrophic (effect on the muscle tone of the urinary bladder and rectum). The use of prostatilen, as an organotropic polypeptide with high tissue specificity, is a justified pharmacological model for the treatment of infectious-inflammatory and congestive conditions in the structures of the prostate-vesicular complex in men of various ages. The positive effect of prostatilen is due to a series of complementary pathogenetic mechanisms, which include anti-inflammatory, immunotropic, trophic and neurovascular effects on the above structures. The clinical effect of the rectal form of prostatilen, demonstrated in cases of a combination of chronic prostatitis with benign prostatic hyperplasia and confirmed by a series of long-term studies, makes it possible to use it both in mono- and in combination therapy of these conditions, taking into account the individual conditions of the course of the disease.

Antrodan, A β-glucan obtained from Antrodia cinnamomea mycelia, is beneficial to benign prostate hyperplasia

2015 ◽  
Vol 6 (2) ◽  
pp. 635-645 ◽  
Author(s):  
Chiung-Chi Peng ◽  
Yi-Ting Lin ◽  
Kuan-Chou Chen ◽  
Charng-Cherng Chyau ◽  
Robert Y. Peng
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Benign Prostate Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Prostate Hyperplasia ◽  
Antrodia Cinnamomea ◽  
Benign Prostate

Benign prostatic hyperplasia (BPH), one of the most common disease usually occurring in men in their 50s, has now become an atypical direct cause of mortality.

Evaluating how much dutasteride actually reduces serum dihydrotestosterone level: A Reconsideration based on unexpected results from a study of treatment of benign prostatic hyperplasia with dutasteride

2020 ◽  
pp. 205141582092630
Author(s):  
Masanori Nukui
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Sex Hormones ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Level Of Evidence ◽  
Prostate Hyperplasia ◽  
Natural Decrease ◽  
One Year ◽  
Benign Prostate

Objective: This study aimed to evaluate the effect of dutasteride treatment of benign prostatic hyperplasia on serum steroidal sex hormones and prostate volume (PV). Methods: Thirty patients with benign prostate hyperplasia treated with dutasteride for one year were assessed for changes in PV and serum sex hormones (testosterone (T), dihydotestosterone (DHT), estradiol (E2) and dehydroepiandrosterone sulphate (DHEAS)). PV was measured by ultrasonography. A paired or unpaired t-test and Pearson’s correlation coefficient test were used for statistical analysis. Results: DHT and DHEAS decreased by 38.5% and 20.3%, respectively. On the contrary, T and E2 increased by 34.3% and 9.4%, respectively. PV and prostate-specific antigen decreased by 17.7% and 63.4%, respectively. The rate of decrease of DHT had a negative correlation with PV, and the rate of decrease of DHEAS had positive correlation with PV. Conclusion: DHT did not decrease as expected (previous studies showed a decrease of approximately 90%). However, DHEAS decreased more than a natural decrease. It is possible that the conversion from DHEAS to DHT, via the conversion to T, in the prostate was accelerated by the decrease of DHT, especially in larger prostates. However, this discrepancy cannot be full explained by the conversion from DHEAS to DHT, as mentioned above. Level of evidence: Level 2c

scholarly journals Picture Of Age Factors And Sexual Activity With The Incidence Of Benign Prostate Hyperplasia

2017 ◽  
Vol 1 (2) ◽  
pp. 16-25
Author(s):  
Hamdana ◽  
Fatmawati
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Sexual Activity ◽  
Sampling Method ◽  
Age Factors ◽  
Prostatic Hyperplasia ◽  
Benign Disease ◽  
Prostate Hyperplasia ◽  
Descriptive Approach ◽  
The Right ◽  
Benign Prostate

In Indonesia Prostate Hyperplasia Benigna Based on the autopsy rate of microscopic changes at the age of 30-40 years. When microscopic changes develop, anatomic pathologic changes occur in men aged 50 years, the incidence rate is around 50%. 80 years old around 80% and 90 years old 100%. Prevalence increases because of an increase in life expectancy. The results of a survey conducted on Benigna Prostate Hyperplasia patients at H. Andi Sulthan Daeng Radja Hospital in Bulukumba District, patients with Benigna Prostate Hyperplasia have an average age of> 50 years as many as 30 people. This study aims to determine the description of age and sexual activity with the incidence of hyperplasia prostate benign disease in H. Andi Sulthan Daeng Radja District Hospital. This study uses a descriptive approach with a population of 30 and is sampled. Sampling using the Total Sampling method. The results of research on the incidence of prostate hyperplasia benign disease mostly occur with age and partial sexual activity who experience benign prostatic hyperplasia more normal sexual activity 1-2 times/weeks and only a few are abnormal sex frequency. The conclusion of the study is the age category of the initial elderly as many as 7 people (23.3%), the final elderly as many as 8 people (26.7%). While the age of seniors as many as 15 people (50%) the category of normal sex frequency <3 times/week as many as 16 respondents (53.3%) and as many as 14 respondents (46.7%) who do sexual frequency> 3 times a week. The suggestion from this research is that it should pay attention to various aspects that can influence the occurrence of hyperplasia prostate benign in patients so that its incidence can be prevented and can provide good service, as well as the right action for sufferers of benign prostatic hyperplasia.

scholarly journals The Significance of PSA/IGF-1 Ratio in Differentiating Benign Prostate Hyperplasia from Prostate Cancer

2000 ◽  
Vol 16 (3-4) ◽  
pp. 143-146 ◽  
Author(s):  
G. Koliakos ◽  
D. Chatzivasiliou ◽  
Th. Dimopoulos ◽  
V. Trachana ◽  
K. Paschalidou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Roc Analysis ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Prostate Hyperplasia ◽  
Patients With Cancer ◽  
Free Psa ◽  
Benign Prostate

The importance of insulin-like growth factor 1 (IGF-1) in human serum for the early diagnosis of prostate cancer is controversial. The IGF-1/PSA ratio may improve the performance of prostate specific antigen (PSA) as a prostate cancer marker. IGF-1, along with PSA and free PSA concentration, was measured in the serum of 34 patients with prostate cancer and in 131 patients with benign prostatic hyperplasia (BPH). Although IGF-1 concentration did not significantly differ between the groups, PSA/IGF-1 ratio could clearly distinguish the two groups. In patients with cancer but not in patients with BPH, IGF-1 concentration correlated with PSA and free PSA. The values of PSA and free PSA correlated with each other for both groups. Receivers Operating Curve (ROC) analysis indicated a better sensitivity to specificity ratio for PSA/IGF-1 than for PSA or Free/Total (F/T) PSA.

scholarly journals HIGH POWER TRANSURETHRAL THULIUM:YAG LASER VAPOENUCLEATION OF PROSTATE – A NEW STANDARD IN BENIGN PROSTATE HYPERPLASIA SURGERY

InterConf ◽  
2021 ◽  
pp. 281-289
Author(s):  
Alexei Plesacov ◽  
Ivan Vladanov ◽  
Vitalii Ghicavii
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
High Power ◽  
Benign Prostate Hyperplasia ◽  
Postoperative Recovery ◽  
Minimal Invasive ◽  
Prostatic Hyperplasia ◽  
Surgical Trauma ◽  
Prostate Hyperplasia ◽  
Invasive Techniques ◽  
Benign Prostate

According to current reccomandations, open adenomectomy is considered the most efficient surgical option for patients with large benign prostatic hyperplasia. In order to reduce surgical trauma and to improuve postoperative recovery, there have been proposed several minimally invasive techniques for the treatment of large benign prostatic hyperplasia, the most innovative being laser surgery. High power Thulium:YAG laser vapoenucleation of prostate is becoming popular for minimal invasive surgical management of benign prostate hyperplasia.

Use of laser technologies in surgical treatment of benign prostate hyperplasia

2021 ◽  
pp. 36-45
Author(s):  
Mark Albertovich Volodin ◽  
Evgeny Nikolaevich Bolgov ◽  
Maya A. Kuzmina ◽  
Darya Dmitrievna Vasina
Keyword(s):  
Surgical Treatment ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Surgical Instruments ◽  
Prostate Hyperplasia ◽  
Minimum Diameter ◽  
Surgical Interventions ◽  
Laser Technologies ◽  
Laser Devices ◽  
Benign Prostate

The use of laser technology in the surgical treatment of patients with benign prostatic hyperplasia has recently become widespread and introduced into practice. This area of surgery uses a large range of laser modifications and methods of their application when performing surgical interventions on the prostate. The article discusses laser devices for minimally invasive operations on patients with benign prostatic hyperplasia in comparison with traditional methods of BPH surgical treatment. The advantages of using laser technologies include the reduction of the time of surgical intervention, the decrease in the number of traumatic complications and bleeding, the absence of the damaging effect of the shock wave, the possibility of using it with surgical instruments of the minimum diameter, and the possibility of using it with flexible surgical instruments.

Monopolar vs. Bipolar Trans Urethral Resection of Prostrate (TURP) - A Comparative Outcome Analysis in Benign Prostatic Hyperplasia - A Single Centre Experience in Western Odisha

2021 ◽  
Vol 8 (31) ◽  
pp. 2875-2879
Author(s):  
Sucheta Panigrahi ◽  
Acharya Suryakanta Pattajoshi ◽  
Sanjay Kumar Mahapatra ◽  
Raja Kumar Subudhi P ◽  
Biswajit Sahu
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Operating Time ◽  
Prostatic Hyperplasia ◽  
Outcome Analysis ◽  
Symptom Improvement ◽  
P Value ◽  
Urinary Flow ◽  
Prostate Hyperplasia ◽  
Bipolar Group ◽  
Post Operative Period

BACKGROUND In this study we wanted to compare the clinical outcomes in terms of symptom improvement and perioperative results of monopolar and bipolar trans urethral resection of prostrate (TURP) for benign prostatic hyperplasia (BPH) and evaluate the advantages of bipolar transurethral resection over the monopolar resection. METHODS A total of 150 patients who underwent trans urethral resection of prostate (TURP) surgical procedure, (n = 75 for monopolar TURP) and (n = 75 for bipolar TURP) for BPH enrolled between December 2018 to November 2020 at the Department of Urology in VSSIMSAR, Burla, Odisha. RESULTS Significant differences were found in operating time in minutes (45.11 ± 4.029 vs 41.99 ± 5.020, P < 0.025) between monopolar and bipolar TURP. The mean sodium falls in post-operative period in bipolar and monopolar TURP was 7 Meq and 3 Meq respectively which was statistically significant (P - value less than 0.05). Bipolar TURP is equally effective as monopolar in reducing the international prostate symptom score (IPSS), improvement in quality of life, maximum urinary flow rate. Trans urethral resection (TUR) syndrome was reported in two patients who had undergone monopolar resection without any incidence in bipolar group. 3 patients in monopolar group developed clot retention compared to 1 in bipolar group in post-operative period. Fall in haemoglobin (Hb) and packed cell volume (PCV) was more with monopolar group but insignificant. CONCLUSIONS Bipolar TURP is safe and equally effective as monopolar TURP with advantage of shorter operative time and absence of dilutional hyponatremia and TUR syndrome, but needs large randomized trials with long follow up to confirm its efficacy and safety. KEYWORDS Monopolar TURP; Bipolar TURP; Benign Prostate Hyperplasia

Sign in / Sign up

Export Citation Format

Share Document